Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of Sunday, August 23, 2026.
Forward PE Ratio (N/A) = Close Price ($146.12) / Consensus Forward EPS ($-0.47)
FORWARD PE RATIO
N/A
Gilead Sciences, Inc.
Market Cap
$181.42B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Gilead Sciences, Inc. (GILD) | $181.42B | N/A |
| Abbott Laboratories (ABT)vs › | $201.83B | 21.14 |
| Pfizer Inc. (PFE)vs › | $159.98B | 9.44 |
| Novo Nordisk A/S (NVO)vs › | $207.55B | N/A |
| Danaher Corporation (DHR)vs › | $153.85B | 25.74 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $139.10B | 29.24 |
| Bristol-Myers Squibb Company (BMY)vs › | $136.88B | 9.67 |
| Intuitive Surgical, Inc. (ISRG)vs › | $133.83B | 35.08 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $233.85B | 25.06 |
| Stryker Corporation (SYK)vs › | $126.30B | 21.93 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
At today's $146.12 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.47 | $-0.64 – $-0.28 | 15 | n/m |
| 2027-12-31 | $9.90 | $7.91 – $11.29 | 16 | 14.8x |
| 2028-12-31 | $10.67 | $9.16 – $12.18 | 10 | 13.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
